Yuhan said on May 6 that it signed a contract with U.S.-based Bridge Biopharma to supply active pharmaceutical ingredients (APIs) for a cardiomyopathy treatment.
The contract is worth about $38,076,000 (560 billion won), equivalent to 2.56% of Yuhan's sales last year (2.1866 trillion won). The contract runs from May 5, 2026, to Mar. 1, 2028.
Bridge Biopharma is a U.S. Nasdaq-listed biotech company developing treatments for genetic diseases and cardiovascular diseases.
※ This article has been translated by AI. Share your feedback here.